Screening for the presence of aberrantly expressed ACTR2 in osteosarcoma and analyzing its mechanism of action

Min Yi1,2, Kai Zheng3,4, Qian Ning2,4

  • 1Department of Orthopedic Surgery, West China Hospital, Sichuan University Chengdu 610041, Sichuan, China.

PubMed

Insights

Osteosarcoma (OS) is a prevalent bone cancer. Lower levels of ARP2 actin-related protein 2 homolog (ACTR2) in patients indicate poor prognosis and can aid diagnosis. ACTR2 also impacts cancer cell behavior and apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma (OS) is the most common primary malignant bone tumor.
  • Understanding its molecular pathogenesis is crucial for diagnosis and treatment.
  • Differentially expressed genes (DEGs) in OS present potential therapeutic targets.

Purpose of the Study:

  • To investigate the role of ARP2 actin-related protein 2 homolog (ACTR2) in osteosarcoma.
  • To evaluate ACTR2 as a diagnostic and prognostic biomarker for OS.
  • To explore the regulatory relationship between ACTR2 and miR-374a-5p in OS cells.

Main Methods:

  • Analysis of the GSE16088 dataset to identify DEGs.
  • Quantitative evaluation of ACTR2 expression in patient blood and tissues.
  • In vitro studies using gene transfection and dual-luciferase reporter assays.

Main Results:

  • ACTR2 was significantly downregulated in OS patients and tissues compared to controls.
  • Low ACTR2 expression correlated with poorer patient survival.
  • Elevating ACTR2 or suppressing miR-374a-5p inhibited OS cell proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT), while enhancing apoptosis.
  • A direct regulatory interaction between ACTR2 and miR-374a-5p was confirmed.

Conclusions:

  • ACTR2 serves as a potential diagnostic and prognostic biomarker for osteosarcoma.
  • The ACTR2/miR-374a-5p axis plays a significant role in regulating OS cell behavior.
  • Targeting this pathway may offer new therapeutic strategies for osteosarcoma.